Discover
PMVP
PMV Pharmaceuticals, Inc.
1.24
2 x 0.96
2 x 1.54
bid
ask
-
0.10
7.46%
2 @ 04:00 PM
1.25 +0.01 (0.81%)
| Ytd | -0.80% | |
| 1y | 18.10% |
1.20
day range
1.34
1.02
52 week range
1.88
| Open | 1.34 | Prev Close | 1.34 | Low | 1.20 | High | 1.34 | Mkt Cap | 66.13M |
| Vol | 253.82K | Avg Vol | 368.46K | EPS | -1.48 | P/E | N/A | Forward P/E | -0.96 |
| Beta | 1.48 | Short Ratio | 5.17 | Inst. Own | 83.89% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 1.26 | 200-d Avg | 1.30 | 1yr Est | 5.80 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -0.35 | -0.37 | -0.02 | -5.71% |
| 2024-08-08 | 2024-06 | -0.34 | -0.02 | 0.32 | 94.12% |
| 2024-08-08 | 2024-06 | -0.34 | N/A | N/A | N/A |
| 2024-05-09 | 2024-03 | -0.35 | -0.3 | 0.05 | 14.29% |
| 2024-05-09 | 2024-03 | -0.35 | N/A | N/A | N/A |
| 2024-02-29 | 2023-12 | -0.39 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-08-20 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-30 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-13 | Craig-Hallum | Upgrade | Buy | |
| 2024-04-12 | Jefferies | Upgrade | Buy | |
| 2024-03-07 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-09-14 | ALLAND LEILA | Officer | 45.91K | Sale |
| 2024-09-10 | CARULLI MICHAEL | Chief Financial Officer | 88.40K | Sale |
| 2024-09-10 | JALOTA DEEPIKA | Officer | 118.28K | Sale |
| 2024-01-17 | MACK DAVID HENRY | Chief Executive Officer | 812.66K | Stock Award(Grant) |
| 2023-11-21 | ORBIMED ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Orbimed Advisors LLC. | 6.48M | 9.78M | 12.51% |
| 2024-09-29 | ArrowMark Colorado Holdings LLC | 3.65M | 5.51M | 7.05% |
| 2024-09-29 | Sio Capital Management, LLC | 3.21M | 4.85M | 6.21% |
| 2024-09-29 | Euclidean Capital Llc | 2.63M | 3.97M | 5.08% |
| 2024-09-29 | Alkeon Capital Management LLC | 2.34M | 3.54M | 4.53% |
| 2024-09-29 | Vanguard Group Inc | 2.28M | 3.44M | 4.41% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 1.52M | 2.30M | 2.95% |
| 2024-09-29 | Meridian Small Cap Growth Fund | 1.26M | 1.90M | 2.43% |
| 2024-09-29 | ACAP Strategic Fund | 1.15M | 1.73M | 2.22% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 540.35K | 815.93K | 1.04% |
| 2024-09-29 | Advantage Advisers Xanthus Fund, LLC | 329.95K | 498.22K | 0.64% |
| 2024-08-30 | BlackRock Advantage Small Cap Core Fund | 280.45K | 423.47K | 0.54% |